๐ ็ธฝ็ฎ้ ๏ฝ ๐ ่ฑๆๅๆ๏ผๆฌ็ฏ๏ผ ๏ฝ ๐ ๅฎๆด็ฟป่ญฏ ๏ฝ โญ ็ฒพ่ฏ็ญ่จ
INTRODUCTION
The Nobel Prize in Medicine was awarded in 1950 to Hench and associates for their initial work on the beneficial effects and toxicities of corticosteroids for rheumatic disorders. In 1951, Sulzberger and colleagues first reported the use of systemic cortisone and adrenocorticotropic hormone (ACTH) as therapies for inflammatory skin diseases. One year later, Sulzberger and Witten successfully treated eczematous eruptions with topical hydrocortisone. A novel method of high-dose glucocorticoid therapy was introduced to dermatology in 1982 by Johnson and Lazarus, who used pulse intravenous therapy for pyoderma gangrenosum. During the past 40 years, a variety of other anti-inflammatory/immunomodulatory drugs have been developed, allowing for a โsteroid-sparingโ effect and minimization of risks from long-term therapy with systemic glucocorticoids.